<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Int J Chron Obstruct Pulmon Dis</journal-id>
<journal-id journal-id-type="iso-abbrev">Int J Chron Obstruct Pulmon Dis</journal-id>
<journal-id journal-id-type="publisher-id">COPD</journal-id>
<journal-id journal-id-type="pmc">copd</journal-id>
<journal-title-group>
<journal-title>International Journal of Chronic Obstructive Pulmonary Disease</journal-title>
</journal-title-group>
<issn pub-type="ppub">1176-9106</issn>
<issn pub-type="epub">1178-2005</issn>
<publisher>
<publisher-name>Dove</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">32764909</article-id>
<article-id pub-id-type="pmc">7360408</article-id>
<article-id pub-id-type="publisher-id">245617</article-id>
<article-id pub-id-type="doi">10.2147/COPD.S245617</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Research</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Exploration of n-6 and n-3 Polyunsaturated Fatty Acids Metabolites Associated with Nutritional Levels in Patients with Severe Stable Chronic Obstructive Pulmonary Disease</article-title>
<alt-title alt-title-type="running-authors">Xue et al</alt-title>
<alt-title alt-title-type="running-title">Xue et al</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Xue</surname>
<given-names>Mingshan</given-names>
</name>
<xref ref-type="aff" rid="AFF0001">1</xref>
<xref ref-type="author-notes" rid="FT0001"></xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Cai</surname>
<given-names>Chuanxu</given-names>
</name>
<xref ref-type="aff" rid="AFF0002">2</xref>
<xref ref-type="author-notes" rid="FT0001"></xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Guan</surname>
<given-names>Lili</given-names>
</name>
<xref ref-type="aff" rid="AFF0001">1</xref>
<xref ref-type="author-notes" rid="FT0001"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Xu</surname>
<given-names>Yifan</given-names>
</name>
<xref ref-type="aff" rid="AFF0001">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lin</surname>
<given-names>Jinsheng</given-names>
</name>
<xref ref-type="aff" rid="AFF0001">1</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0003-2615-5994</contrib-id>
<name>
<surname>Zeng</surname>
<given-names>Yifeng</given-names>
</name>
<xref ref-type="aff" rid="AFF0001">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hu</surname>
<given-names>Haisheng</given-names>
</name>
<xref ref-type="aff" rid="AFF0001">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Rongchang</given-names>
</name>
<xref ref-type="aff" rid="AFF0001">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Hongman</given-names>
</name>
<xref ref-type="aff" rid="AFF0003">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhou</surname>
<given-names>Luqian</given-names>
</name>
<xref ref-type="aff" rid="AFF0001">1</xref>
<xref ref-type="corresp" rid="AN0001"></xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0002-1671-0723</contrib-id>
<name>
<surname>Sun</surname>
<given-names>Baoqing</given-names>
</name>
<xref ref-type="aff" rid="AFF0001">1</xref>
</contrib>
<aff id="AFF0001"><label>1</label><institution>Guangzhou Institute of Respiratory Health, State Key Laboratory of Respiratory Disease, National Clinical Research Center of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University</institution>, <addr-line>Guangzhou</addr-line>, <country>People’s Republic of China</country></aff>
<aff id="AFF0002"><label>2</label><institution>Department of Laboratory Medicine, Shenzhen Institute of Respiratory Diseases, Shenzhen People’s Hospital, First Affiliated Hospital of Southern University of Science and Technology, Second Clinical Medical College of Jinan University</institution>, <addr-line>Shenzhen</addr-line>, <country>People’s Republic of China</country></aff>
<aff id="AFF0003"><label>3</label><institution>Department of Respiratory and Critical Care Medicine, The Fifth Affiliated Hospital of Zunyi Medical University Zhuhai</institution>, <addr-line>Zhuhai</addr-line>, <country>People’s Republic of China</country></aff>
</contrib-group>
<author-notes>
<corresp id="AN0001">Correspondence: Luqian Zhou; Baoqing Sun Email zhlx09@163.com; sunbaoqing@vip.163.com</corresp>
<fn id="FT0001">
<label>*</label>
<p>These authors contributed equally to this work</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>10</day>
<month>7</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="collection">
<year>2020</year>
</pub-date>
<volume>15</volume>
<fpage>1633</fpage>
<lpage>1642</lpage>
<history>
<date date-type="received">
<day>11</day>
<month>1</month>
<year>2020</year>
</date>
<date date-type="accepted">
<day>30</day>
<month>4</month>
<year>2020</year>
</date>
</history>
<permissions>
<copyright-statement>© 2020 Xue et al.</copyright-statement>
<copyright-year>2020</copyright-year>
<copyright-holder>Xue et al.</copyright-holder>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
<license-p>This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at <ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link> and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (<ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link>).</license-p>
</license>
</permissions>
<abstract>
<sec id="S2001">
<title>Background and Objective</title>
<p>Severe chronic obstructive pulmonary disease (COPD) is the terminal stage of the disease characterized by declined lung function, malnutrition, and poor prognosis. Such patients cannot tolerate long-time sports rehabilitation owing to dyspnea and fail to achieve the desired therapeutic effect; therefore, increasing nutritional support will be an important strategy for them. The present study applied metabolomics technology to evaluate the correlation between serum concentrations of polyunsaturated fatty acid (PUFA) metabolites, nutritional status, and lung function in patients with COPD to provide a theoretical basis for accurate nutritional support.</p>
</sec>
<sec id="S2002">
<title>Materials and Methods</title>
<p>We enrolled 82 patients with stable severe COPD in our hospital. The general characteristics including height, weight, and lung function were recorded. Metabolomics was used to detect the concentrations of serum metabolites of n-3 and n-6 at baseline and at 24 and 52 weeks after enrollment. The correlations between nutrition level and pulmonary function and clinical indicators were evaluated.</p>
</sec>
<sec id="S2003">
<title>Results</title>
<p>The concentrations of n-3 and n-6 increased over time along with the progression of COPD. Body mass index (BMI) and percent of ideal body weight (IBW%) decreased with disease development, and BMI was found to be significantly correlated with FEV1% predicted and FEV1/FVC. Serum levels of n-6 metabolites such as linoleic acid (LA), γ-linoleic acid (GLA), and arachidonic acid (ARA) (all <italic>P</italic> &lt; 0.01) and the n-3 metabolites such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (all <italic>P</italic> &lt; 0.05) showed significant correlations with BMI and were closely correlated with FEV1% predicted and FEV1/FVC of lung function (all <italic>P</italic>&lt; 0.05).</p>
</sec>
<sec id="S2004">
<title>Conclusion</title>
<p>This study demonstrates that malnutrition in patients with severe COPD is progressive and is positively correlated with n-3 and n-6 polyunsaturated fatty acids and lung function.</p>
</sec>
</abstract>
<kwd-group kwd-group-type="author">
<title>Keywords</title>
<kwd>chronic obstructive pulmonary disease</kwd>
<kwd>metabolomics</kwd>
<kwd>nutritional level</kwd>
</kwd-group>
<counts>
<fig-count count="4"></fig-count>
<table-count count="2"></table-count>
<ref-count count="62"></ref-count>
<page-count count="10"></page-count>
</counts>
</article-meta>
</front>
<body>
<sec id="S0001" sec-type="intro">
<title>Introduction</title>
<p>Chronic obstructive pulmonary disease (COPD) is a common chronic inflammatory disease of the lungs, characterized by incomplete and persistent limitation of airflow and progressive aggravation over time.<xref ref-type="bibr" rid="CIT0001">1</xref>–<xref ref-type="bibr" rid="CIT0004">4</xref> Accumulation of inflammatory cells and inflammatory cytokines in the respiratory tract can have adverse effects on the lungs including in the decline of lung function.<xref ref-type="bibr" rid="CIT0005">5</xref>,<xref ref-type="bibr" rid="CIT0006">6</xref> The persistent inflammation and increased effort required for breathing increase patients’ energy expenditure.<xref ref-type="bibr" rid="CIT0007">7</xref> Furthermore, inappetence and anxiety can lead to reduced energy intake, leading to malnutrition.<xref ref-type="bibr" rid="CIT0008">8</xref> Most patients with COPD exist in a state of protein malnutrition, and reductions in muscle mass and myofiber strength mean that the normal function of respiratory muscles are reduced. This leads to a decline in lung compliance, thus accelerating disease progression.<xref ref-type="bibr" rid="CIT0009">9</xref></p>
<p>Pulmonary rehabilitation has become an important strategy in the management of COPD, and can remarkably improve the quality of life and long-term prognosis of patients.<xref ref-type="bibr" rid="CIT0010">10</xref> However, some patients with severe COPD and poor adherence to treatment may not tolerate this treatment.<xref ref-type="bibr" rid="CIT0010">10</xref>,<xref ref-type="bibr" rid="CIT0011">11</xref> Therefore, such patients are most suited to drug therapy in clinical practice.<xref ref-type="bibr" rid="CIT0011">11</xref>,<xref ref-type="bibr" rid="CIT0012">12</xref> The Global Initiative for Chronic Obstructive Lung Disease (GOLD) suggests that patients with grade 3–4 COPD would benefit from nutritional support during lung rehabilitation.<xref ref-type="bibr" rid="CIT0010">10</xref>,<xref ref-type="bibr" rid="CIT0013">13</xref>-<xref ref-type="bibr" rid="CIT0015">15</xref> Purposeful adjustment of nutritional intake could improve prognosis and reduce acute episodes and the length of readmissions.<xref ref-type="bibr" rid="CIT0016">16</xref></p>
<p>Studies have shown that high-calorie diets or the maintenance of obesity can improve lung function of some patients with COPD, whereas excessive ingestion result in the obesity will exacerbate hypoxia.<xref ref-type="bibr" rid="CIT0008">8</xref>,<xref ref-type="bibr" rid="CIT0017">17</xref>,<xref ref-type="bibr" rid="CIT0018">18</xref> Therefore, it is crucial to assess the nutritional level of patients before pulmonary rehabilitation ingestion intervention (the level and ratio of essential fatty acids), which is the basis of targeted nutrient schemes.<xref ref-type="bibr" rid="CIT0019">19</xref>–<xref ref-type="bibr" rid="CIT0021">21</xref></p>
<p>As an important branch of systems biology, metabolomics can be used to elucidate the mechanisms underlying disease development, by providing solid biological evidence for personalized and precision medicine.<xref ref-type="bibr" rid="CIT0022">22</xref>,<xref ref-type="bibr" rid="CIT0023">23</xref> Metabolomics has obvious advantages for COPD, a disease with a complex phenotype for which the physiological mechanism is unknown. The approach also plays a key role in determining appropriate nutritional support for chronic diseases.<xref ref-type="bibr" rid="CIT0024">24</xref>,<xref ref-type="bibr" rid="CIT0025">25</xref> As a non-invasive test, metabolomics has great potential for investigations into the influence nutrient intake and the identification of biomarkers during disease progression.<xref ref-type="bibr" rid="CIT0026">26</xref></p>
<p>For humans, n-3 and n-6 polyunsaturated fatty acids (PUFAs) are indispensable components of the daily diet, and are essential for maintaining normal physiological functions.<xref ref-type="bibr" rid="CIT0027">27</xref>,<xref ref-type="bibr" rid="CIT0028">28</xref> The metabolites of n-3 PUFAs possess anti-inflammatory activities, which could attenuate the partial pro-inflammatory effects of n-6; thus, consuming n-3-rich foods can reduce inflammation to some extent.<xref ref-type="bibr" rid="CIT0029">29</xref>–<xref ref-type="bibr" rid="CIT0031">31</xref> Furthermore, n-6 PUFAs are involved in a variety of physiological and pathological processes, acting as the immediate precursor of thrombin, leukotriene, and prostacyclin, and are responsible for regulating the persistent inflammation of COPD.<xref ref-type="bibr" rid="CIT0027">27</xref> Interestingly, because of homeostasis, increased intake of n-3 or n-6 does not significantly affect the amount of metabolites produced or the secretion of downstream inflammatory markers.<xref ref-type="bibr" rid="CIT0032">32</xref>–<xref ref-type="bibr" rid="CIT0037">37</xref></p>
</sec>
<sec id="S0002">
<title>Materials and Methods</title>
<sec id="S0002-S2001">
<title>Study Design and Patients</title>
<p>For the present retrospective case-control study, we recruited all consecutive patients with severe stable COPD (the diagnostic criteria met the latest 2020 Global Initiative for Chronic Obstructive Lung Disease reports) who were treated at our institute from October 2016 to June 2017 and met the following inclusion criteria: 1) aged 70–80, 2) forced expiratory volume in 1 second (FEV1) &lt;50% and FEV1/forced vital capacity (FVC) ≤0.7, 3) no history of immune-related respiratory disease or extrapulmonary disease involving the lungs and 4) no history of diabetes or hypertension. Written signed informed consent was obtained from all patients before enrollment. Each patient underwent a 52-week follow-up, and serum samples were taken and clinical data collected from all participants at baseline, 24 weeks and 52 weeks. In addition, 29 healthy volunteers were recruited as healthy control subjects. This experiment was approved by the Ethics Committee of the First Affiliated Hospital of Guangzhou Medical University (NCT04042519). This study follows the ethical principles contained in the current version of the Helsinki declaration.</p>
</sec>
<sec id="S0002-S2002">
<title>Lung Function Test</title>
<p>According to the requirements of the American Thoracic Society and the European Respiratory Society (ATS/ERS), pulmonary function tests were performed on participants using the Jaeger lung function instrument (MasterScreen, Leibnizstrasse, Hoechberg, Germany). Parameters included: FEV1, FVC, FEV1/FVC, total vital capacity, and total lung capacity (TLC). These indicators were used to diagnose and monitor COPD progression according to ATS/ERS criteria.<xref ref-type="bibr" rid="CIT0037">37</xref></p>
</sec>
<sec id="S0002-S2003">
<title>Collection and Storage of Blood Samples</title>
<p>Participants underwent venous blood collection. Samples were centrifuged at 3000 r/min (1006.2 xg) for 10 min and 20 degrees Celsius. The resulting serum was sub-packed and stored at –80°C which for no longer than 2 years prior to use. Repeated freezing and thawing was avoided for metabolomics research.</p>
</sec>
<sec id="S0002-S2004">
<title>Measurement of Metabolites by Ultra-Performance Liquid Chromatography/Time-of-Flight Mass Spectrometry</title>
<p>An Agilent 1290 Infinity LC system (Santa Clara, CA, USA) was used for targeted determination of metabolites in serum samples, and radiolabeled compound hydroxy-eicosatetraenoic acid-d8 and prostaglandin D<sub>2</sub>-d4 (Ann Arbor, Michigan USA, Caymen) were used. The Metabolites were classified and matched according to the Kyoto Encyclopedia of Genes and Genomes (KEGG, Bioinformatics Center, Institute for Chemical Research, Kyoto University and Human Genome Center, Institute of Medical Science) and The Human Metabolome Database (HMDB4.0, University of Alberta, Edmonton, Canada). We used Agilent MassHunter Workstation Software Qualitative Analysis B.05.00 based on retention time, mass-charge ratio, and other molecular characteristics to analyze metabolite peak areas.</p>
</sec>
<sec id="S0002-S2005">
<title>Statistical Analysis</title>
<p>Data were analyzed and graphed using SPSS (Statistics for Windows Version 22.0, IBM Corp, Chicago, IL, USA), GraphPadPrism 5.0 (GraphPad Software, San Diego, CA, USA), MedCalc, version 18.11 (MedCalc Software Inc., Acacialaan, Ostend, Belgium) and R-studio. The website Metaboanalyst (Xia Lab, McGill University) was used to create metabolite diagrams. Data are presented as the median ± standard deviation, evaluated using standardized indicators. Comparison of metabolites at each of the time points was analyzed using analysis of variance (ANOVA). We considered <italic>P</italic> &lt; 0.05 to be statistically significant.</p>
</sec>
</sec>
<sec id="S0003">
<title>Results</title>
<sec id="S0003-S2001">
<title>Participants and Clinical Characteristics</title>
<p><xref ref-type="table" rid="T0001">Table 1</xref> presents the background characteristics of the study population, which included 82 patients with COPD. There were no significant differences in gender, age, or body mass index (BMI) between the two groups. Percent of ideal body weight (IBW%) was significantly different in the COPD group are compared with the normal group (<italic>P</italic> &lt; 0.05). The pulmonary function parameters, including FVC% predicted, FEV1% predicted, and the FEV1/FVC ratios were signiﬁcantly lower in patients with COPD than in healthy controls. The COPD group was evaluated at three time points: baseline, 24 weeks, and 52 weeks after enrollment. The BMI and IBW% decreased over time, as did the percentage of FEV1 in the predicted value (FEV1 pred%) and FEV1/FVC. Neutrophil and white blood cell counts were significantly higher in the COPD group than the normal controls (<italic>P</italic> &lt; 0.05).<table-wrap id="T0001" orientation="portrait" position="float"><label>Table 1</label><caption><p>Participant Characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="2"></th><th colspan="1" rowspan="2">Healthy Control</th><th colspan="4" rowspan="1">COPD Group</th></tr><tr><th colspan="1" rowspan="1">Baseline</th><th colspan="1" rowspan="1">24 Weeks</th><th colspan="1" rowspan="1">52 Weeks</th><th colspan="1" rowspan="1">P value</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">N</td><td colspan="1" rowspan="1">29</td><td colspan="1" rowspan="1">82</td><td colspan="1" rowspan="1">82</td><td colspan="1" rowspan="1">82</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Age</td><td colspan="1" rowspan="1">60±9.83</td><td colspan="1" rowspan="1">66±10.59</td><td colspan="1" rowspan="1">66±10.59</td><td colspan="1" rowspan="1">67±10.59</td><td colspan="1" rowspan="1">0.659</td></tr><tr><td colspan="1" rowspan="1">Male/Female</td><td colspan="1" rowspan="1">26/3</td><td colspan="1" rowspan="1">76/6</td><td colspan="1" rowspan="1">76/6</td><td colspan="1" rowspan="1">76/6</td><td colspan="1" rowspan="1">0.988</td></tr><tr><td colspan="1" rowspan="1">BMI</td><td colspan="1" rowspan="1">24.91±3.10</td><td colspan="1" rowspan="1">26.33±5.29</td><td colspan="1" rowspan="1">23.32±4.77</td><td colspan="1" rowspan="1">22.34±3.61</td><td colspan="1" rowspan="1">0.669</td></tr><tr><td colspan="1" rowspan="1">IBW%</td><td colspan="1" rowspan="1">100.7±16.38</td><td colspan="1" rowspan="1">108.9±19.28</td><td colspan="1" rowspan="1">99.78±17.44</td><td colspan="1" rowspan="1">96.33±15.81</td><td colspan="1" rowspan="1">0.001</td></tr><tr><td colspan="1" rowspan="1">WBC (10^9)</td><td colspan="1" rowspan="1">6.24±5.57</td><td colspan="1" rowspan="1">6.08±4.31</td><td colspan="1" rowspan="1">7.49±3.59</td><td colspan="1" rowspan="1">7.82±6.85</td><td colspan="1" rowspan="1">0.038</td></tr><tr><td colspan="1" rowspan="1">NEUT (10^9)</td><td colspan="1" rowspan="1">5.13±1.22</td><td colspan="1" rowspan="1">5.29±3.16</td><td colspan="1" rowspan="1">5.85±2.94</td><td colspan="1" rowspan="1">5.41±3.15</td><td colspan="1" rowspan="1">0.11</td></tr><tr><td colspan="1" rowspan="1">TLC (10^9)</td><td colspan="1" rowspan="1">1.37±1.61</td><td colspan="1" rowspan="1">1.35±0.60</td><td colspan="1" rowspan="1">1.27±0.67</td><td colspan="1" rowspan="1">1.36±0.73</td><td colspan="1" rowspan="1">0.644</td></tr><tr><td colspan="1" rowspan="1">Eos (10^9)</td><td colspan="1" rowspan="1">0.19±0.31</td><td colspan="1" rowspan="1">0.14±0.12</td><td colspan="1" rowspan="1">0.16±0.27</td><td colspan="1" rowspan="1">0.12±0.16</td><td colspan="1" rowspan="1">0.121</td></tr><tr><td colspan="1" rowspan="1">CRP (μg/L)</td><td colspan="1" rowspan="1">0.12±1.61</td><td colspan="1" rowspan="1">0.39±0.14</td><td colspan="1" rowspan="1">0.26±0.31</td><td colspan="1" rowspan="1">0.42±0.17</td><td colspan="1" rowspan="1">0.492</td></tr><tr><td colspan="1" rowspan="1">PCT (ng/mL)</td><td colspan="1" rowspan="1">0.20±1.46</td><td colspan="1" rowspan="1">0.21±0.75</td><td colspan="1" rowspan="1">0.31±1.10</td><td colspan="1" rowspan="1">0.27±1.07</td><td colspan="1" rowspan="1">0.342</td></tr><tr><td colspan="1" rowspan="1">CEA (ng/mL)</td><td colspan="1" rowspan="1">4.43±4.78</td><td colspan="1" rowspan="1">3.80±2.90</td><td colspan="1" rowspan="1">4.75±6.36</td><td colspan="1" rowspan="1">3.20±2.26</td><td colspan="1" rowspan="1">0.285</td></tr><tr><td colspan="1" rowspan="1">Glu (mmol/L)</td><td colspan="1" rowspan="1">6.12±5.56</td><td colspan="1" rowspan="1">6.15±2.29</td><td colspan="1" rowspan="1">6.35±3.26</td><td colspan="1" rowspan="1">6.21±1.82</td><td colspan="1" rowspan="1">0.561</td></tr><tr><td colspan="1" rowspan="1">TCH (mmol/L)</td><td colspan="1" rowspan="1">3.71±5.54</td><td colspan="1" rowspan="1">3.92±1.19</td><td colspan="1" rowspan="1">4.27±1.01</td><td colspan="1" rowspan="1">3.97±0.89</td><td colspan="1" rowspan="1">0.077</td></tr><tr><td colspan="1" rowspan="1">FEV1 (% predict)</td><td colspan="1" rowspan="1">91.68±4.50</td><td colspan="1" rowspan="1">58.10±12.86</td><td colspan="1" rowspan="1">34.10±9.07</td><td colspan="1" rowspan="1">23.85±7.84</td><td colspan="1" rowspan="1">0.001</td></tr><tr><td colspan="1" rowspan="1">FVC (% predict)</td><td colspan="1" rowspan="1">90.33±4.63</td><td colspan="1" rowspan="1">69.45±15.89</td><td colspan="1" rowspan="1">71.15±14.11</td><td colspan="1" rowspan="1">72.00±16.96</td><td colspan="1" rowspan="1">0.832</td></tr><tr><td colspan="1" rowspan="1">FEV1/FVC%</td><td colspan="1" rowspan="1">82.52±8.71</td><td colspan="1" rowspan="1">56.01±6.97</td><td colspan="1" rowspan="1">43.22±4.12</td><td colspan="1" rowspan="1">36.19±5.89</td><td colspan="1" rowspan="1">0.001</td></tr></tbody></table><table-wrap-foot><fn><p><bold>Abbreviations:</bold> COPD, chronic obstructive pulmonary disease; BMI, body mass index; IBW, ideal body weight; WBC, white blood cell count; TLC, total lymphocyte count; NEUT, neutrophile granulocyte; EOS, eosinophilic granulocyte; CRP, C-reactive protein; PCT, procalcitonin; CEA, carcinoembryonic antigen; GLU, glucose; TCH, total cholesterol; FEV1, forced expiratory volume in 1second; FVC, forced vital capacity.</p></fn></table-wrap-foot></table-wrap>
</p>
</sec>
<sec id="S0003-S2002">
<title>Nutritional Status of Patients with Chronic Obstructive Pulmonary Disease</title>
<p>The body mass index (BMI) and ideal body weight percentage (IBW%) of patients with severe stable COPD declined over time (<xref ref-type="fig" rid="F0001">Figure 1</xref>), and BMI was significantly correlated with FEV1% predicted and FEV1/FVC (r=0.18 and r= 0.23 respectively, all <italic>P</italic> &lt; 0.01).<fig fig-type="figure" id="F0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>(<bold>A</bold>) and (<bold>B</bold>) Trends of BMI and IBW% in COPD patients at baseline, 24 W, and 52 W; (<bold>C</bold>) BMI was significantly correlated with FEV1% predicted and FEV1/FVC.</p></caption><graphic content-type="print-only" xlink:href="COPD-15-1633-g0001"></graphic></fig></p>
</sec>
<sec id="S0003-S2003">
<title>Metabolites of n-3 and n-6 Polyunsaturated Fatty Acids</title>
<p><xref ref-type="table" rid="T0002">Table 2</xref> presents the results of analysis of each metabolite at each of the time points. <xref ref-type="fig" rid="F0002">Figure 2</xref> illustrates the general trends of n-3 and n-6 metabolites; the concentration of linoleic acid (LA), gamma-linoleic acid (GLA), and di-homo gamma-linoleic acid (DGLA) increased progressively over the three time points in patients with COPD. The concentration of the eicosanoic acid metabolites 5-hydroperoxyeicosatetraenoic acid (5-HPETE), 5-hydroxyeicosatetraenoic acid (5-HETE), and 12-HETE with arachidonic acid (ARA) as the immediate substrate were also increased over three follow-up time points in the study. The concentration of n-3 alpha-linoleic acid (ALA) and eicosapentaenoic aced (EPA) increased over time, while docosapentaenoic acid (DPA), docosahexaenoic acid (DHA), tetracosapentaenoic acid (TPA) and tetracosahexaenoic acid (THA) declined over time. <xref ref-type="fig" rid="F0003">Figure 3</xref> shows the pathway diagram of the metabolites detected in this study. In addition, the levels of n-3 and n-6 in healthy control subjects were lower than COPD patients.<table-wrap id="T0002" orientation="portrait" position="float"><label>Table 2</label><caption><p>Peak Ratio of n-3 and n-6 Metabolites</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="2">Metabolites</th><th colspan="1" rowspan="2">Total Peak Ratio</th><th colspan="3" rowspan="1">Peak Ratio at Different Times</th><th colspan="1" rowspan="2"><italic>F</italic></th><th colspan="1" rowspan="2"><italic>P</italic> value</th></tr><tr><th colspan="1" rowspan="1">Baseline</th><th colspan="1" rowspan="1">24 Weeks</th><th colspan="1" rowspan="1">56 Weeks</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">ALA</td><td colspan="1" rowspan="1">8.94±5.51</td><td colspan="1" rowspan="1">5.02±3.62</td><td colspan="1" rowspan="1">7.86±4.26</td><td colspan="1" rowspan="1">13.15±5.61</td><td colspan="1" rowspan="1">5.02</td><td colspan="1" rowspan="1">0.032</td></tr><tr><td colspan="1" rowspan="1">EPA</td><td colspan="1" rowspan="1">32.93±51.43</td><td colspan="1" rowspan="1">12.15±19.74</td><td colspan="1" rowspan="1">39.55±34.16</td><td colspan="1" rowspan="1">59.44±63.51</td><td colspan="1" rowspan="1">32.77</td><td colspan="1" rowspan="1">0.001</td></tr><tr><td colspan="1" rowspan="1">DHA</td><td colspan="1" rowspan="1">272.1±163.7</td><td colspan="1" rowspan="1">246.6±128.7</td><td colspan="1" rowspan="1">266.7±187.6</td><td colspan="1" rowspan="1">323.3±157.2</td><td colspan="1" rowspan="1">26.05</td><td colspan="1" rowspan="1">0.001</td></tr><tr><td colspan="1" rowspan="1">Stearidonic</td><td colspan="1" rowspan="1">46.96±33.40</td><td colspan="1" rowspan="1">49.86±28.93</td><td colspan="1" rowspan="1">45.15±36.85</td><td colspan="1" rowspan="1">47.00±34.69</td><td colspan="1" rowspan="1">0.19</td><td colspan="1" rowspan="1">0.082</td></tr><tr><td colspan="1" rowspan="1">Nisinic</td><td colspan="1" rowspan="1">23.21±18.68</td><td colspan="1" rowspan="1">17.77±12.46</td><td colspan="1" rowspan="1">25.95±19.10</td><td colspan="1" rowspan="1">27.77±20.53</td><td colspan="1" rowspan="1">41.47</td><td colspan="1" rowspan="1">0.001</td></tr><tr><td colspan="1" rowspan="1">DPA</td><td colspan="1" rowspan="1">9.03±5.22</td><td colspan="1" rowspan="1">7.35±3.45</td><td colspan="1" rowspan="1">8.68±4.43</td><td colspan="1" rowspan="1">11.05±6.059</td><td colspan="1" rowspan="1">32.53</td><td colspan="1" rowspan="1">0.015</td></tr><tr><td colspan="1" rowspan="1">TPA</td><td colspan="1" rowspan="1">63.33±36.70</td><td colspan="1" rowspan="1">76.33±39.97</td><td colspan="1" rowspan="1">62.76±36.22</td><td colspan="1" rowspan="1">49.85±28.39</td><td colspan="1" rowspan="1">12.54</td><td colspan="1" rowspan="1">0.136</td></tr><tr><td colspan="1" rowspan="1">THA</td><td colspan="1" rowspan="1">6.69±5.96</td><td colspan="1" rowspan="1">7.08±5.57</td><td colspan="1" rowspan="1">7.79±7.21</td><td colspan="1" rowspan="1">5.89±2.79</td><td colspan="1" rowspan="1">16.34</td><td colspan="1" rowspan="1">0.078</td></tr><tr><td colspan="1" rowspan="1">LA</td><td colspan="1" rowspan="1">2459±2324</td><td colspan="1" rowspan="1">1952±859.1</td><td colspan="1" rowspan="1">2426±1082</td><td colspan="1" rowspan="1">3348±3614</td><td colspan="1" rowspan="1">36.59</td><td colspan="1" rowspan="1">0.001</td></tr><tr><td colspan="1" rowspan="1">GLA</td><td colspan="1" rowspan="1">463.2±309.7</td><td colspan="1" rowspan="1">272.1±189.4</td><td colspan="1" rowspan="1">434.4±172.9</td><td colspan="1" rowspan="1">600.7±399.1</td><td colspan="1" rowspan="1">38.87</td><td colspan="1" rowspan="1">0.001</td></tr><tr><td colspan="1" rowspan="1">DGLA</td><td colspan="1" rowspan="1">1.25±0.96</td><td colspan="1" rowspan="1">1.02±0.60</td><td colspan="1" rowspan="1">1.262±1.03</td><td colspan="1" rowspan="1">1.49±1.02</td><td colspan="1" rowspan="1">6.97</td><td colspan="1" rowspan="1">0.023</td></tr><tr><td colspan="1" rowspan="1">ARA</td><td colspan="1" rowspan="1">122.2±240.4</td><td colspan="1" rowspan="1">26.91±73.21</td><td colspan="1" rowspan="1">122.2±113.7</td><td colspan="1" rowspan="1">509.9±205.3</td><td colspan="1" rowspan="1">240.07</td><td colspan="1" rowspan="1">0.001</td></tr><tr><td colspan="1" rowspan="1">Adrenic acid</td><td colspan="1" rowspan="1">79.18±70.26</td><td colspan="1" rowspan="1">67.60±33.46</td><td colspan="1" rowspan="1">79.49±56.67</td><td colspan="1" rowspan="1">99.69±93.98</td><td colspan="1" rowspan="1">32.30</td><td colspan="1" rowspan="1">0.001</td></tr><tr><td colspan="1" rowspan="1">Osbond acid</td><td colspan="1" rowspan="1">45.97±41.22</td><td colspan="1" rowspan="1">44.80±44.78</td><td colspan="1" rowspan="1">48.98±40.50</td><td colspan="1" rowspan="1">45.7±38.58</td><td colspan="1" rowspan="1">0.15</td><td colspan="1" rowspan="1">0.804</td></tr><tr><td colspan="1" rowspan="1">5s-HPETE</td><td colspan="1" rowspan="1">1.02±1.25</td><td colspan="1" rowspan="1">0.40±0.69</td><td colspan="1" rowspan="1">1.22±0.99</td><td colspan="1" rowspan="1">1.42±1.52</td><td colspan="1" rowspan="1">2.69</td><td colspan="1" rowspan="1">0.022</td></tr><tr><td colspan="1" rowspan="1">12s-HPETE</td><td colspan="1" rowspan="1">0.45±1.09</td><td colspan="1" rowspan="1">0.04±0.23</td><td colspan="1" rowspan="1">0.69±0.74</td><td colspan="1" rowspan="1">1.883±1.208</td><td colspan="1" rowspan="1">4.81</td><td colspan="1" rowspan="1">0.364</td></tr><tr><td colspan="1" rowspan="1">15s-HPETE</td><td colspan="1" rowspan="1">0.05±0.32</td><td colspan="1" rowspan="1">0.03±0.07</td><td colspan="1" rowspan="1">0.09±0.51</td><td colspan="1" rowspan="1">0.04±0.13</td><td colspan="1" rowspan="1">5.26</td><td colspan="1" rowspan="1">0.631</td></tr><tr><td colspan="1" rowspan="1">12s-HETE</td><td colspan="1" rowspan="1">2.87±6.28</td><td colspan="1" rowspan="1">1.31±2.85</td><td colspan="1" rowspan="1">3.08±5.61</td><td colspan="1" rowspan="1">5.45±8.04</td><td colspan="1" rowspan="1">3.27</td><td colspan="1" rowspan="1">0.024</td></tr><tr><td colspan="1" rowspan="1">15s-HETE</td><td colspan="1" rowspan="1">2.73±8.76</td><td colspan="1" rowspan="1">0.244±2.34</td><td colspan="1" rowspan="1">3.10±6.33</td><td colspan="1" rowspan="1">4.91±12.68</td><td colspan="1" rowspan="1">17.27</td><td colspan="1" rowspan="1">0.130</td></tr><tr><td colspan="1" rowspan="1">5s-HETE</td><td colspan="1" rowspan="1">22.42±17.43</td><td colspan="1" rowspan="1">11.88±9.35</td><td colspan="1" rowspan="1">25.02±15.45</td><td colspan="1" rowspan="1">30.01±19.53</td><td colspan="1" rowspan="1">37.16</td><td colspan="1" rowspan="1">0.001</td></tr></tbody></table><table-wrap-foot><fn><p><bold>Abbreviations:</bold> ALA, α-linolenic acid; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; DPA, docosapentaenoic acid; TPA, tetracosapentaenoic acid; THA, tetracosahexaenoic acid; LA, α-linolenic acid; GLA, γ-linolenic acid; DGLA, dihomo-γ-linolenic acid; ARA, arachidonic acid; HETE, hydroxy-eicosatetraenoic acid; HPETE, hydroperoxy-eicotetraenoic acid.</p></fn></table-wrap-foot></table-wrap>
<fig fig-type="figure" id="F0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Levels of n-3 and n-6 at different stages of COPD progression. The heatmap shows different metabolite levels at baseline, 24 W, and 52 W in patients with severely stable COPD.</p><p><bold>Abbreviations:</bold> EPA, eicosapentaenoic acid; DPA, docosapentaenoic acid; DHA, docosahexenoic acid; TPA, tetracosapentaenoic aicd; THA, tetracosahexaenoic acid; LA, linoleic acid; GLA, γ-linolenic acid; DGLA, dihomo-γ-linolenic acid; ARA, arachidonic acid; HETE, hydroxy-eicosatetraenoic acid; HPETE, hydrogen peroxide eicarboxylic acid.</p></caption><graphic content-type="print-only" xlink:href="COPD-15-1633-g0002"></graphic></fig><fig fig-type="figure" id="F0003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Pathway maps of n-3 and n-6 metabolism.</p></caption><graphic content-type="print-only" xlink:href="COPD-15-1633-g0003"></graphic></fig></p>
</sec>
<sec id="S0003-S2004">
<title>Correlation Between Metabolite Levels and Lung Function in Patients with Chronic Obstructive Pulmonary Disease</title>
<p>The n-6 metabolites LA, GLA, and ARA showed significant correlations with BMI (r = −0.23, −0.58, and −0.11, respectively, all <italic>P</italic> &lt; 0.01), while EPA, DHA of n-3 metabolites were also significantly correlated with BMI (r = −0.54, −0.30, respectively, all <italic>P</italic> &lt; 0.05). All those metabolites including LA, GLA, ARA, EPA and DHA were closely correlated with FEV1% predicted (r = −0.37, −0.35, −0.60, −0.47, −0.19, all <italic>P</italic>&lt; 0.05) and FEV1/FVC (r = −0.26, −0.13, −0.44, −0.28, −0.72, respectively, all <italic>P</italic>&lt; 0.05) (<xref ref-type="fig" rid="F0004">Figure 4</xref>). In addition, the total contents of n-3 and n-6 were found to be significantly correlated with FEV1/FVC (all <italic>P</italic> &lt; 0.05).<fig fig-type="figure" id="F0004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Correlation between n-3 and n-6 metabolites and lung function. The n-6 metabolites LA, GLA, and ARA showed significant correlations with BMI (r = −0.23, −0.58, and −0.11, respectively, all <italic>P</italic> &lt; 0.01), while EPA, DHA of n-3 metabolites were also significantly correlated with BMI (r = −0.54, −0.30, respectively, all <italic>P</italic> &lt; 0.05). All those metabolites including LA, GLA, ARA, EPA and DHA were closely correlated with FEV1% predicted (r = −0.37, −0.35, −0.60, −0.47, −0.19, all <italic>P</italic>&lt; 0.05) and FEV1/FVC (r = −0.26, −0.13, −0.44, −0.28, −0.72, respectively, all <italic>P</italic>&lt;0.05).</p></caption><graphic content-type="print-only" xlink:href="COPD-15-1633-g0004"></graphic></fig></p>
</sec>
</sec>
<sec id="S0004">
<title>Discussion</title>
<p>In this study, we observed at three time points that inflammation levels increased with the progression of COPD and lung ventilation function decreased. Meanwhile, patient nutritional levels declined over time. The total content of n-3 and n-6 PUFAs rose over time, and were significantly correlated with lung function, BMI, and IBW%. Therefore, n-3 and n-6 metabolites may represent novel evaluation indicators for nutritional support during pulmonary rehabilitation in patients with COPD.</p>
<sec id="S0004-S2001">
<title>The Relationship Between Nutrient Levels and Disease Progression in Patients with Chronic Obstructive Pulmonary Disease</title>
<p>Through the evaluation of BMI and IBW% at three follow-up time points, we found that the nutritional level of patients with severe stable COPD decreased gradually as the disease advanced, and was significantly correlated with the FEV1% predicted and FEV1/FVC. Malnutrition is one of the risk factors for persistent disease progression in patients with COPD.<xref ref-type="bibr" rid="CIT0004">4</xref> Weight loss is a common extrapulmonary manifestation, and BMI and IBW% are simple, precise, and repeatable indicators of nutritional levels.<xref ref-type="bibr" rid="CIT0004">4</xref>,<xref ref-type="bibr" rid="CIT0039">39</xref>,<xref ref-type="bibr" rid="CIT0040">40</xref> As COPD progresses, respiratory work generally increases, as does anxiety and anorexia, which lead to decreased nutrient intake and impaired lung ventilation.<xref ref-type="bibr" rid="CIT0041">41</xref>,<xref ref-type="bibr" rid="CIT0042">42</xref> Furthermore, malnutrition leads to decreased immune function and inflammatory damage to the normal structure of the bronchoalveoli, which result in decreased lung function and accelerated disease progression. <xref ref-type="bibr" rid="CIT0038">38</xref>,<xref ref-type="bibr" rid="CIT0043">43</xref>,<xref ref-type="bibr" rid="CIT0044">44</xref> Therefore, we believe that nutritional support during pulmonary rehabilitation is crucial to end the negative cycle.</p>
<p>The sources of n-3 PUFAs mainly include deep-sea fish, shrimp, and beef, while n-6 PUFAs are mainly found in sunflower seeds, soybean oil, and meat.<xref ref-type="bibr" rid="CIT0045">45</xref> Saini et al<xref ref-type="bibr" rid="CIT0046">46</xref> reported that eating n-6-rich foods may increase the risk of chronic diseases, which may be antagonized by consumption of n-3 PUFAs. As essential fatty acids, the n-3 and n-6 are closely related to the level of inflammation, especially in the case of COPD. Roman et al<xref ref-type="bibr" rid="CIT0047">47</xref> and Wood et al<xref ref-type="bibr" rid="CIT0048">48</xref> reported that n-3 PUFAs can interfere with the process of chronic airway inflammation due to their anti-inflammatory properties. Many nutrition studies have also suggested the importance of the ratio of n-3 to n-6 in the formula of nutritional support for patients with COPD.<xref ref-type="bibr" rid="CIT0004">4</xref>,<xref ref-type="bibr" rid="CIT0035">35</xref>,<xref ref-type="bibr" rid="CIT0049">49</xref>-<xref ref-type="bibr" rid="CIT0051">51</xref> At present, this is the first longitudinal study to simultaneously evaluate the metabolites of n-3 and n-6 level in severe stable COPD patients.</p>
</sec>
<sec id="S0004-S2002">
<title>The Relationship Between n-3 and n-6 Metabolites with Disease Progression</title>
<p>We identified an increase over time in the total content of n-3 and n-6 in serum samples. The anti-inflammatory activity of n-3 has been demonstrated in the context of various chronic inflammatory lung diseases, and can contribute to the reduction of neutrophil numbers in the lungs.<xref ref-type="bibr" rid="CIT0028">28</xref>,<xref ref-type="bibr" rid="CIT0052">52</xref>,<xref ref-type="bibr" rid="CIT0053">53</xref> The n-6 PUFAs have pro-inflammatory effects and act as immediate precursors for a variety of potent pro-inflammatory mediators (leukotrienes and prostaglandins), which are responsible for airway remodeling and the destruction of alveolar structure.<xref ref-type="bibr" rid="CIT0006">6</xref>,<xref ref-type="bibr" rid="CIT0054">54</xref></p>
<p>We identified a correlation between n-3 and n-6 PUFAs and lung function, indicating an imbalance between pro- and anti-inflammatory effects; thus, the total inflammation increases and lung function decreases. The overall concentrations of n-3 and n-6 PUFAs in serum samples reflect the data of their antagonistic actions in metabolism reported by Calder et al and Leuti et al.<xref ref-type="bibr" rid="CIT0030">30</xref>,<xref ref-type="bibr" rid="CIT0055">55</xref> The concentration of ALA and EPA increased over time, and we speculated that this upregulation may lead to antagonization of the pro-inflammatory activities of n-6 metabolites, as has been mentioned in a previous study by Duvall et al.<xref ref-type="bibr" rid="CIT0052">52</xref> Notably, because of the mechanisms of homeostasis and the intestinal flora, in spite of the concentration of n-3 is on the rise, it does not mean that all category of lipid metabolites on n-3 pathways are all on the rise.<xref ref-type="bibr" rid="CIT0056">56</xref>,<xref ref-type="bibr" rid="CIT0057">57</xref> Although the present study provides some insight, the trends in metabolites of PUFAs in patients with COPD have not been fully elucidated and require further exploration.</p>
</sec>
<sec id="S0004-S2003">
<title>Evaluation of n-3 and n-6 Lipid Metabolites and Nutritional Status in Patients with Chronic Obstructive Pulmonary Disease</title>
<p>The key metabolite of n-6 PUFAs (ARA) and the core metabolites of n-3 PUFAs (EPA and DHA) and the total concentrations of n-3 and n-6 PUFAs were found to be significantly correlated with BMI and IBW, respectively. In addition, these concentrations were significantly correlated with FEV1/FVC and FEV1. Therefore, the nutrient levels of patients with moderate-to-severe COPD decreased with disease progression, and we confirmed that n-3 and n-6 concentration reflected the decline in pulmonary function and could be used to evaluate the nutritional status of patients. Personalized medicine plays a key role in improving the symptoms of COPD; nutritional support and the establishment of a rational diet are of particular importance and require accurate assessment of the nutritional status of patients before a regimen is initiated.<xref ref-type="bibr" rid="CIT0039">39</xref> The emergence of metabolomics has led to rapid developments in dietary therapy, which is gradually moving closer to clinical application.<xref ref-type="bibr" rid="CIT0058">58</xref> Initial results and views have been presented in studies on multiple chronic diseases (diabetes, fatty liver, obesity, and cardiovascular disease);<xref ref-type="bibr" rid="CIT0059">59</xref> therefore, metabolite-trend analysis also has immense potential in the evaluation of the nutriture of patients with severe stable COPD. We believe that the n-3 and n-6 lipid metabolites may represent novel indicators for such evaluation; in particular, EPA, DHA, and ARA, which not only reflect the nutriture of patients but also present a significantly negative correlation with lung function.</p>
</sec>
</sec>
<sec id="S0005">
<title>Conclusion</title>
<p>The EPA (n-3), DHA (n-3) and ARA (n-6), and the total concentration of lipid metabolites of n-3 and n-6 can reflect the nutriture of patients with severe stable COPD, which is closely related to the degree of disease progression. In the future, these may be used as novel indicators for the evaluation of nutrient levels of patients with COPD to inform nutritional support for pulmonary rehabilitation. Future research should focus on establishing a theoretical basis for the development of individualized nutrition programs. Moreover, we found that although there was antagonistic effect between n-3 and n-6, the content of the two does not present a tendency of increasing and decreasing, but that n-3 was also up-regulated to resist the pro-inflammatory effect of n-6. Therefore, the specific trend of metabolites in n-3 and n-6 needs to be further explored.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>This study was funded by Project supported by the Chinese National Natural Science Foundation (81700096; 8196010329; 81871736), Bureau of Traditional Chinese Medicine Scientific Research Project of Guangdong (Project No. 20192048), Science and Technology Innovation Committee Project of Guangzhou (Project No. 201804020043), Key Projects of Guangzhou Education Bureau (Project No. 201831802), and Open Project of State Key Laboratory of Respiratory Disease (Project No. SKLRD-OP-201803, SKLRD-OP-201809). Authors do not intend to share individual deidentified participant data and no study-related documents will be made available.</p>
</ack>
<sec id="S0006" sec-type="COI-statement">
<title>Disclosure</title>
<p>The authors report no conflicts of interest in this work.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="CIT0001">
<label>1.</label>
<mixed-citation publication-type="journal"><string-name><surname>Obeidat</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Sadatsafavi</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Sin</surname>
<given-names>DD</given-names></string-name>. <article-title>Precision health: treating the individual patient with chronic obstructive pulmonary disease</article-title>. <source/><italic toggle="yes">Med J Aust</italic>. <year>2019</year>;<volume>210</volume>(<issue>9</issue>):<fpage>424</fpage>–<lpage>428</lpage>. doi:<pub-id pub-id-type="doi">10.5694/mja2.50138</pub-id><pub-id pub-id-type="pmid">30977152</pub-id></mixed-citation>
</ref>
<ref id="CIT0002">
<label>2.</label>
<mixed-citation publication-type="journal"><string-name><surname>Duffy</surname>
<given-names>SP</given-names></string-name>, <string-name><surname>Criner</surname>
<given-names>GJ</given-names></string-name>. <article-title>Chronic obstructive pulmonary disease: evaluation and management</article-title>. <source/><italic toggle="yes">Med Clin North Am</italic>. <year>2019</year>;<volume>103</volume>:<fpage>453</fpage>–<lpage>461</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.mcna.2018.12.005</pub-id><pub-id pub-id-type="pmid">30955513</pub-id></mixed-citation>
</ref>
<ref id="CIT0003">
<label>3.</label>
<mixed-citation publication-type="journal"><string-name><surname>Rabe</surname>
<given-names>KF</given-names></string-name>, <string-name><surname>Hurd</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Anzueto</surname>
<given-names>A</given-names></string-name>, et al. <article-title>Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary</article-title>. <source/><italic toggle="yes">Am J Respir Crit Care Med</italic>. <year>2007</year>;<volume>176</volume>:<fpage>532</fpage>–<lpage>555</lpage>. doi:<pub-id pub-id-type="doi">10.1164/rccm.200703-456SO</pub-id><pub-id pub-id-type="pmid">17507545</pub-id></mixed-citation>
</ref>
<ref id="CIT0004">
<label>4.</label>
<mixed-citation publication-type="journal"><string-name><surname>Pizzini</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Lunger</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Sonnweber</surname>
<given-names>T</given-names></string-name>, et al. <article-title>The role of omega-3 fatty acids in the setting of coronary artery disease and COPD: a review</article-title>. <source/><italic toggle="yes">Nutrients</italic>. <year>2018</year>;<volume>10</volume>(<issue>12</issue>):<fpage>1864</fpage>. doi:<pub-id pub-id-type="doi">10.3390/nu10121864</pub-id></mixed-citation>
</ref>
<ref id="CIT0005">
<label>5.</label>
<mixed-citation publication-type="journal"><string-name><surname>Maltais</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Decramer</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Casaburi</surname>
<given-names>R</given-names></string-name>, et al. <article-title>An official American thoracic society/european respiratory society statement: update on limb muscle dysfunction in chronic obstructive pulmonary disease</article-title>. <source/><italic toggle="yes">Am J Respir Crit Care Med</italic>. <year>2014</year>;<volume>189</volume>:<fpage>e15</fpage>–<lpage>e62</lpage>. doi:<pub-id pub-id-type="doi">10.1164/rccm.201402-0373ST</pub-id><pub-id pub-id-type="pmid">24787074</pub-id></mixed-citation>
</ref>
<ref id="CIT0006">
<label>6.</label>
<mixed-citation publication-type="journal"><string-name><surname>Barnes</surname>
<given-names>PJ</given-names></string-name>. <article-title>Inflammatory mechanisms in patients with chronic obstructive pulmonary disease</article-title>. <source/><italic toggle="yes">J Allergy Clin Immunol</italic>. <year>2016</year>;<volume>138</volume>:<fpage>16</fpage>–<lpage>27</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jaci.2016.05.011</pub-id><pub-id pub-id-type="pmid">27373322</pub-id></mixed-citation>
</ref>
<ref id="CIT0007">
<label>7.</label>
<mixed-citation publication-type="journal"><string-name><surname>Itoh</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Tsuji</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Nemoto</surname>
<given-names>K</given-names></string-name>, et al. <article-title>Undernutrition in patients with COPD and its treatment</article-title>. <source/><italic toggle="yes">Nutrients</italic>. <year>2013</year>;<volume>5</volume>(<issue>4</issue>):<fpage>1316</fpage>–<lpage>1335</lpage>. doi:<pub-id pub-id-type="doi">10.3390/nu5041316</pub-id><pub-id pub-id-type="pmid">23598440</pub-id></mixed-citation>
</ref>
<ref id="CIT0008">
<label>8.</label>
<mixed-citation publication-type="journal"><string-name><surname>Hodson</surname>
<given-names>M</given-names></string-name>. <article-title>Integrating nutrition into pathways for patients with COPD</article-title>. <source/><italic toggle="yes">Br J Community Nurs</italic>. <year>2016</year>;<volume>21</volume>:<fpage>548</fpage>–<lpage>552</lpage>. doi:<pub-id pub-id-type="doi">10.12968/bjcn.2016.21.11.548</pub-id><pub-id pub-id-type="pmid">27809578</pub-id></mixed-citation>
</ref>
<ref id="CIT0009">
<label>9.</label>
<mixed-citation publication-type="journal"><string-name><surname>Akner</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Cederholm</surname>
<given-names>T</given-names></string-name>. <article-title>Treatment of protein-energy malnutrition in chronic nonmalignant disorders</article-title>. <source/><italic toggle="yes">Am J Clin Nutr</italic>. <year>2001</year>;<volume>74</volume>:<fpage>6</fpage>–<lpage>24</lpage>. doi:<pub-id pub-id-type="doi">10.1093/ajcn/74.1.6</pub-id><pub-id pub-id-type="pmid">11451713</pub-id></mixed-citation>
</ref>
<ref id="CIT0010">
<label>10.</label>
<mixed-citation publication-type="journal"><string-name><surname>Garvey</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Bayles</surname>
<given-names>MP</given-names></string-name>, <string-name><surname>Hamm</surname>
<given-names>LF</given-names></string-name>, et al. <article-title>Pulmonary rehabilitation exercise prescription in chronic obstructive pulmonary disease: review of selected guidelines: an official statement from the American association of cardiovascular and pulmonary rehabilitation</article-title>. <source/><italic toggle="yes">J Cardiopulm Rehabil Prev</italic>. <year>2016</year>;<volume>36</volume>:<fpage>75</fpage>–<lpage>83</lpage>. doi:<pub-id pub-id-type="doi">10.1097/HCR.0000000000000171</pub-id><pub-id pub-id-type="pmid">26906147</pub-id></mixed-citation>
</ref>
<ref id="CIT0011">
<label>11.</label>
<mixed-citation publication-type="journal"><string-name><surname>Ibrahim</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Harvey-Dunstan</surname>
<given-names>TC</given-names></string-name>, <string-name><surname>Greening</surname>
<given-names>NJ</given-names></string-name>. <article-title>Rehabilitation in chronic respiratory diseases: in-hospital and post-exacerbation pulmonary rehabilitation</article-title>. <source/><italic toggle="yes">Respirology</italic>. <year>2019</year>;<volume>24</volume>:<fpage>889</fpage>–<lpage>898</lpage>. doi:<pub-id pub-id-type="doi">10.1111/resp.13516</pub-id><pub-id pub-id-type="pmid">30835884</pub-id></mixed-citation>
</ref>
<ref id="CIT0012">
<label>12.</label>
<mixed-citation publication-type="journal"><string-name><surname>Kim</surname>
<given-names>SH</given-names></string-name>, <string-name><surname>Shin</surname>
<given-names>MJ</given-names></string-name>, <string-name><surname>Shin</surname>
<given-names>YB</given-names></string-name>, et al. <article-title>Sarcopenia associated with chronic obstructive pulmonary disease</article-title>. <source/><italic toggle="yes">J Bone Metab</italic>. <year>2019</year>;<volume>26</volume>:<fpage>65</fpage>–<lpage>74</lpage>. doi:<pub-id pub-id-type="doi">10.11005/jbm.2019.26.2.65</pub-id><pub-id pub-id-type="pmid">31223602</pub-id></mixed-citation>
</ref>
<ref id="CIT0013">
<label>13.</label>
<mixed-citation publication-type="journal"><string-name><surname>Spruit</surname>
<given-names>MA</given-names></string-name>, <string-name><surname>Wouters</surname>
<given-names>EFM</given-names></string-name>. <article-title>Organizational aspects of pulmonary rehabilitation in chronic respiratory diseases</article-title>. <source/><italic toggle="yes">Respirology</italic>. <year>2019</year>;<volume>24</volume>:<fpage>838</fpage>–<lpage>843</lpage>. doi:<pub-id pub-id-type="doi">10.1111/resp.13512</pub-id><pub-id pub-id-type="pmid">30810256</pub-id></mixed-citation>
</ref>
<ref id="CIT0014">
<label>14.</label>
<mixed-citation publication-type="journal"><string-name><surname>Machado</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Quadflieg</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Oliveira</surname>
<given-names>A</given-names></string-name>, et al. <article-title>Exercise training in patients with chronic respiratory diseases: are cardiovascular comorbidities and outcomes taken into account?-A systematic review</article-title>. <source/><italic toggle="yes">J Clin Med</italic>. <year>2019</year>;<volume>8</volume>. doi:<pub-id pub-id-type="doi">10.3390/jcm8091458</pub-id></mixed-citation>
</ref>
<ref id="CIT0015">
<label>15.</label>
<mixed-citation publication-type="journal"><string-name><surname>Nici</surname>
<given-names>L</given-names></string-name>, <string-name><surname>ZuWallack</surname>
<given-names>R</given-names></string-name>. <article-title>Chronic obstructive pulmonary disease-evolving concepts in treatment: advances in pulmonary rehabilitation</article-title>. <source/><italic toggle="yes">Semin Respir Crit Care Med</italic>. <year>2015</year>;<volume>36</volume>:<fpage>567</fpage>–<lpage>574</lpage>. doi:<pub-id pub-id-type="doi">10.1055/s-0035-1555613</pub-id><pub-id pub-id-type="pmid">26238642</pub-id></mixed-citation>
</ref>
<ref id="CIT0016">
<label>16.</label>
<mixed-citation publication-type="journal"><string-name><surname>Rochester</surname>
<given-names>CL</given-names></string-name>. <article-title>Patient assessment and selection for pulmonary rehabilitation</article-title>. <source/><italic toggle="yes">Respirology</italic>. <year>2019</year>;<volume>24</volume>:<fpage>844</fpage>–<lpage>853</lpage>. doi:<pub-id pub-id-type="doi">10.1111/resp.13616</pub-id><pub-id pub-id-type="pmid">31251443</pub-id></mixed-citation>
</ref>
<ref id="CIT0017">
<label>17.</label>
<mixed-citation publication-type="journal"><string-name><surname>Dube</surname>
<given-names>BP</given-names></string-name>, <string-name><surname>Laveneziana</surname>
<given-names>P</given-names></string-name>. <article-title>Effects of aging and comorbidities on nutritional status and muscle dysfunction in patients with COPD</article-title>. <source/><italic toggle="yes">J Thorac Dis</italic>. <year>2018</year>;<volume>10</volume>:<fpage>S1355</fpage>–<lpage>S1366</lpage>. doi:<pub-id pub-id-type="doi">10.21037/jtd.2018.02.20</pub-id><pub-id pub-id-type="pmid">29928518</pub-id></mixed-citation>
</ref>
<ref id="CIT0018">
<label>18.</label>
<mixed-citation publication-type="journal"><string-name><surname>Gayan-Ramirez</surname>
<given-names>G</given-names></string-name>. <article-title>Relevance of nutritional support and early rehabilitation in hospitalized patients with COPD</article-title>. <source/><italic toggle="yes">J Thorac Dis</italic>. <year>2018</year>;<volume>10</volume>:<fpage>S1400</fpage>–<lpage>S1414</lpage>. doi:<pub-id pub-id-type="doi">10.21037/jtd.2018.03.167</pub-id><pub-id pub-id-type="pmid">29928522</pub-id></mixed-citation>
</ref>
<ref id="CIT0019">
<label>19.</label>
<mixed-citation publication-type="journal"><string-name><surname>Sokolowski</surname>
<given-names>CM</given-names></string-name>, <string-name><surname>Higgins</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Vishwanathan</surname>
<given-names>M</given-names></string-name>, et al. <article-title>The relationship between animal and plant protein intake and overall diet quality in young adults</article-title>. <source/><italic toggle="yes">Clin Nutr</italic>. <year>2019</year>. doi:<pub-id pub-id-type="doi">10.1016/j.clnu.2019.11.035</pub-id></mixed-citation>
</ref>
<ref id="CIT0020">
<label>20.</label>
<mixed-citation publication-type="journal"><string-name><surname>Bordoni</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Capozzi</surname>
<given-names>F</given-names></string-name>. <article-title>Foodomics for healthy nutrition</article-title>. <source/><italic toggle="yes">Curr Opin Clin Nutr Metab Care</italic>. <year>2014</year>;<volume>17</volume>:<fpage>418</fpage>–<lpage>424</lpage>. doi:<pub-id pub-id-type="doi">10.1097/MCO.0000000000000089</pub-id><pub-id pub-id-type="pmid">25010544</pub-id></mixed-citation>
</ref>
<ref id="CIT0021">
<label>21.</label>
<mixed-citation publication-type="journal"><string-name><surname>Balady</surname>
<given-names>GJ</given-names></string-name>, <string-name><surname>Williams</surname>
<given-names>MA</given-names></string-name>, <string-name><surname>Ades</surname>
<given-names>PA</given-names></string-name>, et al. <article-title>Core components of cardiac rehabilitation/secondary prevention programs: 2007 update: a scientific statement from the American heart association exercise, cardiac rehabilitation, and prevention committee, the council on clinical cardiology; the councils on cardiovascular nursing, epidemiology and prevention, and nutrition, physical activity, and metabolism; and the American association of cardiovascular and pulmonary rehabilitation</article-title>. <source/><italic toggle="yes">J Cardiopulm Rehabil Prev</italic>. <year>2007</year>;<volume>27</volume>:<fpage>121</fpage>–<lpage>129</lpage>. doi:<pub-id pub-id-type="doi">10.1097/01.HCR.0000270696.01635.aa</pub-id><pub-id pub-id-type="pmid">17558191</pub-id></mixed-citation>
</ref>
<ref id="CIT0022">
<label>22.</label>
<mixed-citation publication-type="journal"><string-name><surname>Serkova</surname>
<given-names>NJ</given-names></string-name>, <string-name><surname>Standiford</surname>
<given-names>TJ</given-names></string-name>, <string-name><surname>Stringer</surname>
<given-names>KA</given-names></string-name>. <article-title>The emerging field of quantitative blood metabolomics for biomarker discovery in critical illnesses</article-title>. <source/><italic toggle="yes">Am J Respir Crit Care Med</italic>. <year>2011</year>;<volume>184</volume>:<fpage>647</fpage>–<lpage>655</lpage>. doi:<pub-id pub-id-type="doi">10.1164/rccm.201103-0474CI</pub-id><pub-id pub-id-type="pmid">21680948</pub-id></mixed-citation>
</ref>
<ref id="CIT0023">
<label>23.</label>
<mixed-citation publication-type="journal"><string-name><surname>Cai</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Bian</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Xue</surname>
<given-names>M</given-names></string-name>, et al. <article-title>Eicosanoids metabolized through LOX distinguish asthma-COPD overlap from COPD by metabolomics study</article-title>. <source/><italic toggle="yes">Int J Chron Obstruct Pulmon Dis</italic>. <year>2019</year>;<volume>14</volume>:<fpage>1769</fpage>–<lpage>1778</lpage>. doi:<pub-id pub-id-type="doi">10.2147/COPD.S207023</pub-id><pub-id pub-id-type="pmid">31496676</pub-id></mixed-citation>
</ref>
<ref id="CIT0024">
<label>24.</label>
<mixed-citation publication-type="journal"><string-name><surname>Krishnan</surname>
<given-names>JK</given-names></string-name>, <string-name><surname>Martinez</surname>
<given-names>FJ</given-names></string-name>. <article-title>Lung function trajectories and chronic obstructive pulmonary disease: current understanding and knowledge gaps</article-title>. <source/><italic toggle="yes">Curr Opin Pulm Med</italic>. <year>2018</year>;<volume>24</volume>:<fpage>124</fpage>–<lpage>129</lpage>. doi:<pub-id pub-id-type="doi">10.1097/MCP.0000000000000456</pub-id><pub-id pub-id-type="pmid">29206658</pub-id></mixed-citation>
</ref>
<ref id="CIT0025">
<label>25.</label>
<mixed-citation publication-type="journal"><string-name><surname>Schrimpe-Rutledge</surname>
<given-names>AC</given-names></string-name>, <string-name><surname>Codreanu</surname>
<given-names>SG</given-names></string-name>, <string-name><surname>Sherrod</surname>
<given-names>SD</given-names></string-name>, et al. <article-title>Untargeted metabolomics strategies-challenges and emerging directions</article-title>. <source/><italic toggle="yes">J Am Soc Mass Spectrom</italic>. <year>2016</year>;<volume>27</volume>:<fpage>1897</fpage>–<lpage>1905</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s13361-016-1469-y</pub-id><pub-id pub-id-type="pmid">27624161</pub-id></mixed-citation>
</ref>
<ref id="CIT0026">
<label>26.</label>
<mixed-citation publication-type="journal"><string-name><surname>O’Callaghan</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Noakes</surname>
<given-names>M</given-names></string-name>. <article-title>Meeting report from “frontiers in nutritional science: nutritional metabolomics”</article-title>. <source/><italic toggle="yes">Nutrients</italic>. <year>2014</year>;<volume>6</volume>:<fpage>3451</fpage>–<lpage>3459</lpage>. doi:<pub-id pub-id-type="doi">10.3390/nu6093451</pub-id><pub-id pub-id-type="pmid">25192025</pub-id></mixed-citation>
</ref>
<ref id="CIT0027">
<label>27.</label>
<mixed-citation publication-type="journal"><string-name><surname>Das</surname>
<given-names>UN</given-names></string-name>. <article-title>Ageing: is there a role for arachidonic acid and other bioactive lipids? A review</article-title>. <source/><italic toggle="yes">J Adv Res</italic>. <year>2018</year>;<volume>11</volume>:<fpage>67</fpage>–<lpage>79</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jare.2018.02.004</pub-id><pub-id pub-id-type="pmid">30034877</pub-id></mixed-citation>
</ref>
<ref id="CIT0028">
<label>28.</label>
<mixed-citation publication-type="journal"><string-name><surname>Calder</surname>
<given-names>PC</given-names></string-name>, <string-name><surname>Grimble</surname>
<given-names>RF</given-names></string-name>. <article-title>Polyunsaturated fatty acids, inflammation and immunity</article-title>. <source/><italic toggle="yes">Eur J Clin Nutr</italic>. <year>2002</year>;<volume>56</volume>(<issue>Suppl 3</issue>):<fpage>S14</fpage>–<lpage>S19</lpage>. doi:<pub-id pub-id-type="doi">10.1038/sj.ejcn.1601478</pub-id><pub-id pub-id-type="pmid">12142955</pub-id></mixed-citation>
</ref>
<ref id="CIT0029">
<label>29.</label>
<mixed-citation publication-type="journal"><string-name><surname>Yates</surname>
<given-names>CM</given-names></string-name>, <string-name><surname>Calder</surname>
<given-names>PC</given-names></string-name>, <string-name><surname>Rainger</surname>
<given-names>G</given-names></string-name>. <article-title>Pharmacology and therapeutics of omega-3 polyunsaturated fatty acids in chronic inflammatory disease</article-title>. <source/><italic toggle="yes">Pharmacol Ther</italic>. <year>2014</year>;<volume>141</volume>:<fpage>272</fpage>–<lpage>282</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.pharmthera.2013.10.010</pub-id><pub-id pub-id-type="pmid">24201219</pub-id></mixed-citation>
</ref>
<ref id="CIT0030">
<label>30.</label>
<mixed-citation publication-type="journal"><string-name><surname>Calder</surname>
<given-names>PC</given-names></string-name>. <article-title>Omega-3 fatty acids and inflammatory processes: from molecules to man</article-title>. <source/><italic toggle="yes">Biochem Soc Trans</italic>. <year>2017</year>;<volume>45</volume>:<fpage>1105</fpage>–<lpage>1115</lpage>. doi:<pub-id pub-id-type="doi">10.1042/BST20160474</pub-id><pub-id pub-id-type="pmid">28900017</pub-id></mixed-citation>
</ref>
<ref id="CIT0031">
<label>31.</label>
<mixed-citation publication-type="journal"><string-name><surname>Chilton</surname>
<given-names>FH</given-names></string-name>, <string-name><surname>Dutta</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Reynolds</surname>
<given-names>LM</given-names></string-name>, et al. <article-title>Precision nutrition and omega-3 polyunsaturated fatty acids: a case for personalized supplementation approaches for the prevention and management of human diseases</article-title>. <source/><italic toggle="yes">Nutrients</italic>. <year>2017</year>;<volume>9</volume>(<issue>11</issue>):<fpage>1165</fpage>. doi:<pub-id pub-id-type="doi">10.3390/nu9111165</pub-id></mixed-citation>
</ref>
<ref id="CIT0032">
<label>32.</label>
<mixed-citation publication-type="journal"><string-name><surname>Innes</surname>
<given-names>JK</given-names></string-name>, <string-name><surname>Calder</surname>
<given-names>PC</given-names></string-name>. <article-title>Omega-6 fatty acids and inflammation</article-title>. <source/><italic toggle="yes">Prostaglandins Leukot Essent Fatty Acids</italic>. <year>2018</year>;<volume>132</volume>:<fpage>41</fpage>–<lpage>48</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.plefa.2018.03.004</pub-id><pub-id pub-id-type="pmid">29610056</pub-id></mixed-citation>
</ref>
<ref id="CIT0033">
<label>33.</label>
<mixed-citation publication-type="journal"><string-name><surname>Lemoine</surname>
<given-names>CM</given-names></string-name>, <string-name><surname>Brigham</surname>
<given-names>EP</given-names></string-name>, <string-name><surname>Woo</surname>
<given-names>H</given-names></string-name>, et al. <article-title>Omega-3 fatty acid intake and prevalent respiratory symptoms among U.S. adults with COPD</article-title>. <source/><italic toggle="yes">BMC Pulm Med</italic>. <year>2019</year>;<volume>19</volume>(<issue>1</issue>):<fpage>97</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12890-019-0852-4</pub-id><pub-id pub-id-type="pmid">31122230</pub-id></mixed-citation>
</ref>
<ref id="CIT0034">
<label>34.</label>
<mixed-citation publication-type="journal"><string-name><surname>Johnson</surname>
<given-names>M</given-names></string-name>, <string-name><surname>McElhenney</surname>
<given-names>WH</given-names></string-name>, <string-name><surname>Egnin</surname>
<given-names>M</given-names></string-name>. <article-title>Influence of green leafy vegetables in diets with an elevated omega-6: omega-3 fatty acid ratio on rat blood pressure, plasma lipids, antioxidant status and markers of inflammation</article-title>. <source/><italic toggle="yes">Nutrients</italic>. <year>2019</year>;<volume>11</volume>(<issue>2</issue>):<fpage>301</fpage>. doi:<pub-id pub-id-type="doi">10.3390/nu11020301</pub-id></mixed-citation>
</ref>
<ref id="CIT0035">
<label>35.</label>
<mixed-citation publication-type="journal"><string-name><surname>Simopoulos</surname>
<given-names>AP</given-names></string-name>. <article-title>An Increase in the omega-6/omega-3 fatty acid ratio increases the risk for obesity</article-title>. <source/><italic toggle="yes">Nutrients</italic>. <year>2016</year>;<volume>8</volume>:<fpage>128</fpage>. doi:<pub-id pub-id-type="doi">10.3390/nu8030128</pub-id><pub-id pub-id-type="pmid">26950145</pub-id></mixed-citation>
</ref>
<ref id="CIT0036">
<label>36.</label>
<mixed-citation publication-type="journal"><string-name><surname>Franzosa</surname>
<given-names>EA</given-names></string-name>, <string-name><surname>Sirota-Madi</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Avila-Pacheco</surname>
<given-names>J</given-names></string-name>, et al. <article-title>Gut microbiome structure and metabolic activity in inflammatory bowel disease</article-title>. <source/><italic toggle="yes">Nat Microbiol</italic>. <year>2019</year>;<volume>4</volume>:<fpage>293</fpage>–<lpage>305</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41564-018-0306-4</pub-id><pub-id pub-id-type="pmid">30531976</pub-id></mixed-citation>
</ref>
<ref id="CIT0037">
<label>37.</label>
<mixed-citation publication-type="journal"><string-name><surname>Pinto-Plata</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Casanova</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Divo</surname>
<given-names>M</given-names></string-name>, et al. <article-title>Plasma metabolomics and clinical predictors of survival differences in COPD patients</article-title>. <source/><italic toggle="yes">Respir Res</italic>. <year>2019</year>;<volume>20</volume>:<fpage>219</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12931-019-1167-y</pub-id><pub-id pub-id-type="pmid">31615518</pub-id></mixed-citation>
</ref>
<ref id="CIT0038">
<label>38.</label>
<mixed-citation publication-type="journal"><string-name><surname>Celli</surname>
<given-names>BR</given-names></string-name>, <string-name><surname>Decramer</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Wedzicha</surname>
<given-names>JA</given-names></string-name>, et al. <article-title>An official American thoracic society/european respiratory society statement: research questions in COPD</article-title>. <source/><italic toggle="yes">Eur Respir Rev</italic>. <year>2015</year>;<volume>24</volume>:<fpage>159</fpage>–<lpage>172</lpage>. doi:<pub-id pub-id-type="doi">10.1183/16000617.00000315</pub-id><pub-id pub-id-type="pmid">26028628</pub-id></mixed-citation>
</ref>
<ref id="CIT0039">
<label>39.</label>
<mixed-citation publication-type="journal"><string-name><surname>Hancu</surname>
<given-names>A</given-names></string-name>. <article-title>Nutritional status as a risk factor in COPD</article-title>. <source/><italic toggle="yes">Maedica (Buchar)</italic>. <year>2019</year>;<volume>14</volume>:<fpage>140</fpage>–<lpage>143</lpage>. doi:<pub-id pub-id-type="doi">10.26574/maedica.2019.14.2.140</pub-id><pub-id pub-id-type="pmid">31523295</pub-id></mixed-citation>
</ref>
<ref id="CIT0040">
<label>40.</label>
<mixed-citation publication-type="journal"><string-name><surname>Gea</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Barreiro</surname>
<given-names>E</given-names></string-name>. <article-title>Nutritional abnormalities and chronic obstructive pulmonary disease</article-title>. <source/><italic toggle="yes">Int J Tuberc Lung Dis</italic>. <year>2019</year>;<volume>23</volume>:<fpage>531</fpage>–<lpage>532</lpage>. doi:<pub-id pub-id-type="doi">10.5588/ijtld.19.0160</pub-id><pub-id pub-id-type="pmid">31097058</pub-id></mixed-citation>
</ref>
<ref id="CIT0041">
<label>41.</label>
<mixed-citation publication-type="journal"><string-name><surname>Ogan</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Aydemir</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>EV</surname>
<given-names>T</given-names></string-name>, et al. <article-title>Diaphragmatic thickness in chronic obstructive lung disease and relationship with clinical severity parameters</article-title>. <source/><italic toggle="yes">Turk J Med Sci</italic>. <year>2019</year>;<volume>49</volume>:<fpage>1073</fpage>–<lpage>1078</lpage>. doi:<pub-id pub-id-type="doi">10.3906/sag-1901-164</pub-id><pub-id pub-id-type="pmid">31293145</pub-id></mixed-citation>
</ref>
<ref id="CIT0042">
<label>42.</label>
<mixed-citation publication-type="journal"><string-name><surname>Jung</surname>
<given-names>JW</given-names></string-name>, <string-name><surname>Yoon</surname>
<given-names>SW</given-names></string-name>, <string-name><surname>Lee</surname>
<given-names>GE</given-names></string-name>, et al. <article-title>Poor nutritional intake is a dominant factor for weight loss in chronic obstructive pulmonary disease</article-title>. <source/><italic toggle="yes">Int J Tuberc Lung Dis</italic>. <year>2019</year>;<volume>23</volume>:<fpage>631</fpage>–<lpage>637</lpage>. doi:<pub-id pub-id-type="doi">10.5588/ijtld.18.0456</pub-id><pub-id pub-id-type="pmid">31097074</pub-id></mixed-citation>
</ref>
<ref id="CIT0043">
<label>43.</label>
<mixed-citation publication-type="journal"><string-name><surname>Arora</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Madan</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Mohan</surname>
<given-names>A</given-names></string-name>, et al. <article-title>Serum inflammatory markers and nutritional status in patients with stable chronic obstructive pulmonary disease</article-title>. <source/><italic toggle="yes">Lung India</italic>. <year>2019</year>;<volume>36</volume>(<issue>5</issue>):<fpage>393</fpage>–<lpage>398</lpage>. doi:<pub-id pub-id-type="doi">10.4103/lungindia.lungindia_494_18</pub-id><pub-id pub-id-type="pmid">31464210</pub-id></mixed-citation>
</ref>
<ref id="CIT0044">
<label>44.</label>
<mixed-citation publication-type="journal"><string-name><surname>Paplinska-Goryca</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Rubinsztajn</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Nejman-Gryz</surname>
<given-names>P</given-names></string-name>, et al. <article-title>The association between serological features of chronic Chlamydia pneumoniae infection and markers of systemic inflammation and nutrition in COPD patients</article-title>. <source/><italic toggle="yes">Scand J Clin Lab Invest</italic>. <year>2017</year>;<volume>77</volume>(<issue>8</issue>):<fpage>644</fpage>–<lpage>650</lpage>. doi:<pub-id pub-id-type="doi">10.1080/00365513.2017.1393694</pub-id><pub-id pub-id-type="pmid">29069917</pub-id></mixed-citation>
</ref>
<ref id="CIT0045">
<label>45.</label>
<mixed-citation publication-type="journal"><string-name><surname>Russo</surname>
<given-names>GL</given-names></string-name>. <article-title>Dietary n-6 and n-3 polyunsaturated fatty acids: from biochemistry to clinical implications in cardiovascular prevention</article-title>. <source/><italic toggle="yes">Biochem Pharmacol</italic>. <year>2009</year>;<volume>77</volume>:<fpage>937</fpage>–<lpage>946</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.bcp.2008.10.020</pub-id><pub-id pub-id-type="pmid">19022225</pub-id></mixed-citation>
</ref>
<ref id="CIT0046">
<label>46.</label>
<mixed-citation publication-type="journal"><string-name><surname>Saini</surname>
<given-names>RK</given-names></string-name>, <string-name><surname>Keum</surname>
<given-names>YS</given-names></string-name>. <article-title>Omega-3 and omega-6 polyunsaturated fatty acids: dietary sources, metabolism, and significance - a review</article-title>. <source/><italic toggle="yes">Life Sci</italic>. <year>2018</year>;<volume>203</volume>:<fpage>255</fpage>–<lpage>267</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.lfs.2018.04.049</pub-id><pub-id pub-id-type="pmid">29715470</pub-id></mixed-citation>
</ref>
<ref id="CIT0047">
<label>47.</label>
<mixed-citation publication-type="journal"><string-name><surname>Roman</surname>
<given-names>GC</given-names></string-name>, <string-name><surname>Jackson</surname>
<given-names>RE</given-names></string-name>, <string-name><surname>Gadhia</surname>
<given-names>R</given-names></string-name>, et al. <article-title>Mediterranean diet: the role of long-chain omega-3 fatty acids in fish; polyphenols in fruits, vegetables, cereals, coffee, tea, cacao and wine; probiotics and vitamins in prevention of stroke, age-related cognitive decline, and alzheimer disease</article-title>. <source/><italic toggle="yes">Rev Neurol (Paris)</italic>. <year>2019</year>;<volume>175</volume>(<issue>10</issue>):<fpage>724</fpage>–<lpage>741</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.neurol.2019.08.005</pub-id><pub-id pub-id-type="pmid">31521398</pub-id></mixed-citation>
</ref>
<ref id="CIT0048">
<label>48.</label>
<mixed-citation publication-type="journal"><string-name><surname>Wood</surname>
<given-names>LG</given-names></string-name>. <article-title>Omega-3 polyunsaturated fatty acids and chronic obstructive pulmonary disease</article-title>. <source/><italic toggle="yes">Curr Opin Clin Nutr Metab Care</italic>. <year>2015</year>;<volume>18</volume>:<fpage>128</fpage>–<lpage>132</lpage>. doi:<pub-id pub-id-type="doi">10.1097/MCO.0000000000000142</pub-id><pub-id pub-id-type="pmid">25581034</pub-id></mixed-citation>
</ref>
<ref id="CIT0049">
<label>49.</label>
<mixed-citation publication-type="journal"><string-name><surname>Varraso</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Barr</surname>
<given-names>RG</given-names></string-name>, <string-name><surname>Willett</surname>
<given-names>WC</given-names></string-name>, et al. <article-title>Fish intake and risk of chronic obstructive pulmonary disease in 2 large US cohorts</article-title>. <source/><italic toggle="yes">Am J Clin Nutr</italic>. <year>2015</year>;<volume>101</volume>:<fpage>354</fpage>–<lpage>361</lpage>. doi:<pub-id pub-id-type="doi">10.3945/ajcn.114.094516</pub-id><pub-id pub-id-type="pmid">25646333</pub-id></mixed-citation>
</ref>
<ref id="CIT0050">
<label>50.</label>
<mixed-citation publication-type="journal"><string-name><surname>Collins</surname>
<given-names>PF</given-names></string-name>, <string-name><surname>Yang</surname>
<given-names>IA</given-names></string-name>, <string-name><surname>Chang</surname>
<given-names>Y-C</given-names></string-name>, et al. <article-title>Nutritional support in chronic obstructive pulmonary disease (COPD): an evidence update</article-title>. <source/><italic toggle="yes">J Thorac Dis</italic>. <year>2019</year>;<volume>11</volume>(<issue>S17</issue>):<fpage>S2230</fpage>–<lpage>S2237</lpage>. doi:<pub-id pub-id-type="doi">10.21037/jtd.2019.10.41</pub-id><pub-id pub-id-type="pmid">31737350</pub-id></mixed-citation>
</ref>
<ref id="CIT0051">
<label>51.</label>
<mixed-citation publication-type="journal"><string-name><surname>Simopoulos</surname>
<given-names>AP</given-names></string-name>. <article-title>Evolutionary aspects of diet, the omega-6/omega-3 ratio and genetic variation: nutritional implications for chronic diseases</article-title>. <source/><italic toggle="yes">Biomed Pharmacother</italic>. <year>2006</year>;<volume>60</volume>:<fpage>502</fpage>–<lpage>507</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.biopha.2006.07.080</pub-id><pub-id pub-id-type="pmid">17045449</pub-id></mixed-citation>
</ref>
<ref id="CIT0052">
<label>52.</label>
<mixed-citation publication-type="journal"><string-name><surname>Duvall</surname>
<given-names>MG</given-names></string-name>, <string-name><surname>Levy</surname>
<given-names>BD</given-names></string-name>. <article-title>DHA- and EPA-derived resolvins, protectins, and maresins in airway inflammation</article-title>. <source/><italic toggle="yes">Eur J Pharmacol</italic>. <year>2016</year>;<volume>785</volume>:<fpage>144</fpage>–<lpage>155</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ejphar.2015.11.001</pub-id><pub-id pub-id-type="pmid">26546247</pub-id></mixed-citation>
</ref>
<ref id="CIT0053">
<label>53.</label>
<mixed-citation publication-type="journal"><string-name><surname>Abdulnour</surname>
<given-names>RE</given-names></string-name>, <string-name><surname>Dalli</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Colby</surname>
<given-names>JK</given-names></string-name>, et al. <article-title>Maresin 1 biosynthesis during platelet-neutrophil interactions is organ-protective</article-title>. <source/><italic toggle="yes">Proc Natl Acad Sci U S A</italic>. <year>2014</year>;<volume>111</volume>:<fpage>16526</fpage>–<lpage>16531</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.1407123111</pub-id><pub-id pub-id-type="pmid">25369934</pub-id></mixed-citation>
</ref>
<ref id="CIT0054">
<label>54.</label>
<mixed-citation publication-type="journal"><string-name><surname>Rutting</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Papanicolaou</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Xenaki</surname>
<given-names>D</given-names></string-name>, et al. <article-title>Dietary omega-6 polyunsaturated fatty acid arachidonic acid increases inflammation, but inhibits ECM protein expression in COPD</article-title>. <source/><italic toggle="yes">Respir Res</italic>. <year>2018</year>;<volume>19</volume>:<fpage>211</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12931-018-0919-4</pub-id><pub-id pub-id-type="pmid">30390648</pub-id></mixed-citation>
</ref>
<ref id="CIT0055">
<label>55.</label>
<mixed-citation publication-type="journal"><string-name><surname>Leuti</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Maccarrone</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Chiurchiu</surname>
<given-names>V</given-names></string-name>. <article-title>Proresolving lipid mediators: endogenous modulators of oxidative stress</article-title>. <source/><italic toggle="yes">Oxid Med Cell Longev</italic>. <year>2019</year>;<volume>2019</volume>:<fpage>8107265</fpage>. doi:<pub-id pub-id-type="doi">10.1155/2019/8107265</pub-id><pub-id pub-id-type="pmid">31316721</pub-id></mixed-citation>
</ref>
<ref id="CIT0056">
<label>56.</label>
<mixed-citation publication-type="journal"><string-name><surname>Lovewell</surname>
<given-names>RR</given-names></string-name>, <string-name><surname>Sassetti</surname>
<given-names>CM</given-names></string-name>, <string-name><surname>VanderVen</surname>
<given-names>BC</given-names></string-name>. <article-title>Chewing the fat: lipid metabolism and homeostasis during M. tuberculosis infection</article-title>. <source/><italic toggle="yes">Curr Opin Microbiol</italic>. <year>2016</year>;<volume>29</volume>:<fpage>30</fpage>–<lpage>36</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.mib.2015.10.002</pub-id><pub-id pub-id-type="pmid">26544033</pub-id></mixed-citation>
</ref>
<ref id="CIT0057">
<label>57.</label>
<mixed-citation publication-type="journal"><string-name><surname>Sharon</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Cruz</surname>
<given-names>NJ</given-names></string-name>, <string-name><surname>Kang</surname>
<given-names>DW</given-names></string-name>, et al. <article-title>Human gut microbiota from autism spectrum disorder promote behavioral symptoms in mice</article-title>. <source/><italic toggle="yes">Cell</italic>. <year>2019</year>;<volume>177</volume>:<fpage>1600</fpage>–<lpage>1618 e1617</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cell.2019.05.004</pub-id><pub-id pub-id-type="pmid">31150625</pub-id></mixed-citation>
</ref>
<ref id="CIT0058">
<label>58.</label>
<mixed-citation publication-type="journal"><string-name><surname>Shi</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Brunius</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Johansson</surname>
<given-names>I</given-names></string-name>, et al. <article-title>Plasma metabolites associated with healthy nordic dietary indexes and risk of type 2 diabetes-a nested case-control study in a Swedish population</article-title>. <source/><italic toggle="yes">Am J Clin Nutr</italic>. <year>2018</year>;<volume>108</volume>:<fpage>564</fpage>–<lpage>575</lpage>. doi:<pub-id pub-id-type="doi">10.1093/ajcn/nqy145</pub-id><pub-id pub-id-type="pmid">30060042</pub-id></mixed-citation>
</ref>
<ref id="CIT0059">
<label>59.</label>
<mixed-citation publication-type="journal"><string-name><surname>Cheng</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Shah</surname>
<given-names>SH</given-names></string-name>, <string-name><surname>Corwin</surname>
<given-names>EJ</given-names></string-name>, et al. <article-title>Potential impact and study considerations of metabolomics in cardiovascular health and disease: a scientific statement from the American heart association</article-title>. <source/><italic toggle="yes">Circ Cardiovasc Genet</italic>. <year>2017</year>. doi:<pub-id pub-id-type="doi">10.1161/HCG.0000000000000032</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>